entertainment -WSS

entertainment

author：focus 2025-09-02 09:39:03 - browse：9

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Trump cancels press conference intended to dispute Georgia election interference charges

Wikipedia

WSS

Biotech venture capitalists face new demands from investors

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

EU regulator recommends expanding Mounjaro approval to obesity

NIH director takes cautious approach to Biden drug pricing priority

entertainment

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Dewpoint Therapeutics lays off staff after losing partnerships

Malaria cases in Florida and Texas: Here’s what you need to know

Dewpoint Therapeutics lays off staff after losing partnerships

State Dept. review finds Biden bears some blame for Afghanistan failures

Independent physicians launch a new lobbying group

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage today, explained in one chart

Dobbs anniversary: the lost opportunity of abortion as health care

Dewpoint Therapeutics lays off staff after losing partnerships

Wikipedia

Cancer drug shortages' outsize impact on ovarian cancer patients

Cancer drug shortages' outsize impact on ovarian cancer patients

Research misconduct: Proposed new rules face resistance

Trump's false claims about Georgia's 2020 election long debunked

Eli Lilly, Pfizer, and others want in on the online prescription market

Dewpoint Therapeutics lays off staff after losing partnerships

Wikipedia

Wikipedia

leisure time

leisure time